{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fqa-hiv-art-safety-part-1-GXj7x_Bm","width":444,"version":"1.0","type":"rich","title":"Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/7b613735-8317-4c23-9044-7cad7cab5ba9/current-art-mm-podcast-icon-5.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/e5e16b5a-3622-400b-b2f4-5f87e60fd130\" height=\"200\" width=\"100%\" title=\"Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Hear from expert faculty as they answer questions and discuss key considerations when evaluating potential ARV-related toxicities in special populations, including aging patients and populations with cardiometabolic toxicities."}